Skip to Content

Rezonic Approval Status

FDA Approved: No
Brand name: Rezonic
Generic name: casopitant
Company: GlaxoSmithKline
Treatment for: Nausea/Vomiting, Chemotherapy Induced, Nausea/Vomiting, Postoperative

Rezonic (casopitant) is an investigational NK-1 receptor antagonist in development as add-on therapy for the prevention of chemotherapy-induced nausea and vomiting, and also for the prevention of postoperative nausea and vomiting.

Development Status and FDA Approval Process for Rezonic

Sep 28, 2009GSK Provides Update on Regulatory Filings for Zunrisa/Rezonic
May 29, 2008GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic/Zunrisa (Casopitant)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.